Resumen de A new scenario in metastatic renal cell carcinoma: a SOG‑GU consensus

Sergio Vázquez Estévez, Urbano Anido Herranz, Martin Lázaro Quintela, Ovidio Fernández Calvo, N. Fernández Núñez, N. de Dios Álvarez, Silvia Varela Ferreiro, Begoña Campos Balea, Sara Agraso Busto, María Carmen Areses Manrique, Lara Iglesias Docampo, M. Blanco, S. Maciá Escalante, Luis Antón Aparicio

• Background This article describes and compares approved targeted therapies and the newer immunotherapy agents.

  Materials and methods This article especially performs an in-depth review of currently available data for tivozanib, explain- ing its mechanism of action, its safety profile and its role as an efficacy drug in the management of renal cancer.

  Results Despite the fact that the treatment of advanced RCC has been dramatically modified in recent years, durable remis- sions are scarce and it remains a lethal disease. For first- and second-line therapy, there is now growing evidence to guide the selection of the appropriate treatment.

  Conclusions Several TKIs are standard of care at different settings. Among those approved TKIs, tivozanib has similar efficacy than others with a better safety profile. The use of prognostic factors is critical to the selection of optimal therapy.